Tevogen Bio (TVGN) Competitors $1.00 +0.03 (+3.26%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends TVGN vs. AUTL, CGEM, TECX, CRGX, EXAI, VECT, TRML, DNA, PROK, and SGMOShould you be buying Tevogen Bio stock or one of its competitors? The main competitors of Tevogen Bio include Autolus Therapeutics (AUTL), Cullinan Therapeutics (CGEM), Tectonic Therapeutic (TECX), CARGO Therapeutics (CRGX), Exscientia (EXAI), VectivBio (VECT), Tourmaline Bio (TRML), Ginkgo Bioworks (DNA), ProKidney (PROK), and Sangamo Therapeutics (SGMO). These companies are all part of the "biological products, except diagnostic" industry. Tevogen Bio vs. Autolus Therapeutics Cullinan Therapeutics Tectonic Therapeutic CARGO Therapeutics Exscientia VectivBio Tourmaline Bio Ginkgo Bioworks ProKidney Sangamo Therapeutics Autolus Therapeutics (NASDAQ:AUTL) and Tevogen Bio (NASDAQ:TVGN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, community ranking, risk and earnings. Does the media prefer AUTL or TVGN? In the previous week, Tevogen Bio had 3 more articles in the media than Autolus Therapeutics. MarketBeat recorded 6 mentions for Tevogen Bio and 3 mentions for Autolus Therapeutics. Tevogen Bio's average media sentiment score of -0.12 beat Autolus Therapeutics' score of -0.21 indicating that Tevogen Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Tevogen Bio 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Which has more risk and volatility, AUTL or TVGN? Autolus Therapeutics has a beta of 1.98, suggesting that its share price is 98% more volatile than the S&P 500. Comparatively, Tevogen Bio has a beta of -1.36, suggesting that its share price is 236% less volatile than the S&P 500. Is AUTL or TVGN more profitable? Autolus Therapeutics' return on equity of -63.65% beat Tevogen Bio's return on equity.Company Net Margins Return on Equity Return on Assets Autolus TherapeuticsN/A -63.65% -36.54% Tevogen Bio N/A -396.07%749.97% Does the MarketBeat Community prefer AUTL or TVGN? Autolus Therapeutics received 225 more outperform votes than Tevogen Bio when rated by MarketBeat users. However, 100.00% of users gave Tevogen Bio an outperform vote while only 67.87% of users gave Autolus Therapeutics an outperform vote. CompanyUnderperformOutperformAutolus TherapeuticsOutperform Votes22667.87% Underperform Votes10732.13% Tevogen BioOutperform Votes1100.00% Underperform VotesNo Votes Do analysts rate AUTL or TVGN? Autolus Therapeutics presently has a consensus target price of $10.40, indicating a potential upside of 354.15%. Tevogen Bio has a consensus target price of $4.20, indicating a potential upside of 321.69%. Given Autolus Therapeutics' higher possible upside, equities analysts clearly believe Autolus Therapeutics is more favorable than Tevogen Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Autolus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Tevogen Bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of AUTL or TVGN? 72.8% of Autolus Therapeutics shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by company insiders. Comparatively, 56.6% of Tevogen Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has higher earnings & valuation, AUTL or TVGN? Tevogen Bio has lower revenue, but higher earnings than Autolus Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAutolus Therapeutics$10.09M60.39-$208.38M-$1.21-1.89Tevogen BioN/AN/A-$70KN/AN/A SummaryAutolus Therapeutics beats Tevogen Bio on 7 of the 13 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Tevogen Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TVGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TVGN vs. The Competition Export to ExcelMetricTevogen BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$174.35M$2.94B$5.14B$9.08BDividend YieldN/A1.90%5.09%4.23%P/E RatioN/A46.7389.9717.18Price / SalesN/A415.011,116.21116.99Price / CashN/A182.1042.8937.86Price / Book-0.913.894.784.78Net Income-$70,000.00-$42.21M$120.23M$225.60M7 Day Performance-0.40%-2.15%-1.92%-1.23%1 Month Performance-39.27%4.20%11.49%3.36%1 Year PerformanceN/A18.39%30.57%16.60% Tevogen Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TVGNTevogen Bio2.9777 of 5 stars$1.00+3.3%$4.20+321.7%N/A$174.35MN/A0.0017Gap DownAUTLAutolus Therapeutics2.5518 of 5 stars$2.65+6.4%$10.40+292.5%-58.4%$705.14M$1.70M-2.06330CGEMCullinan Therapeutics1.8003 of 5 stars$11.87+1.0%$31.67+166.8%+32.7%$691.17M$18.94M-4.1430News CoverageTECXTectonic Therapeutic2.9296 of 5 stars$45.81+1.1%$72.25+57.7%N/A$675.84MN/A-7.70120Positive NewsCRGXCARGO Therapeutics1.4622 of 5 stars$14.24+3.6%$31.80+123.3%-20.0%$655.44MN/A-3.23116EXAIExscientia1.0615 of 5 stars$4.84+3.2%$7.00+44.6%-20.8%$632.93M$25.60M-3.21280High Trading VolumeVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030TRMLTourmaline Bio2.4402 of 5 stars$22.29+2.2%$54.00+142.3%+8.7%$571.58MN/A-7.7344DNAGinkgo Bioworks0.5512 of 5 stars$9.70+2.8%$4.58-52.8%N/A$557.56M$251.46M-0.721,218Gap DownPROKProKidney2.0368 of 5 stars$1.90+5.6%$4.50+137.5%-15.6%$552.70MN/A-3.553Gap DownSGMOSangamo Therapeutics1.7575 of 5 stars$2.59+26.3%$7.00+170.4%+581.6%$540.20M$176.23M-3.43480Analyst ForecastNews CoverageHigh Trading Volume Related Companies and Tools Related Companies Autolus Therapeutics Competitors Cullinan Therapeutics Competitors Tectonic Therapeutic Competitors CARGO Therapeutics Competitors Exscientia Competitors VectivBio Competitors Tourmaline Bio Competitors Ginkgo Bioworks Competitors ProKidney Competitors Sangamo Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TVGN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tevogen Bio Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tevogen Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
